SeaBeLife is a biotech company that develops drug candidates for acute liver disease and eye disorders, using patented technology that targets cell death pathways to protect or regenerate organs affected by severe pathologies, with a platform of over 150 biologically active molecules that inhibit necroptosis and ferroptosis in pathological conditions.